Table 3. Toxicity for all patients in our study.
| Variables | BLM + TKI (n=24), n (%) | Cisplatin + TKI (n=19), n (%) | TKI alone (n=58) |
|---|---|---|---|
| Leukopenia | |||
| Grade I–II | 2 (8.3) | 1 (5.3) | 0 (0) |
| Grade III–IV | 0 (0) | 1 (5.3) | 0 (0) |
| Neutropenia | |||
| Grade I–II | 1 (4.2) | 0 (0) | 0 (0) |
| Grade III–IV | 0 (0) | 0 (0) | 0 (0) |
| Anemia | |||
| Grade I–II | 2 (8.3) | 1 (5.3) | 0 (0) |
| Grade III–IV | 0 (0) | 0 (0) | 0 (0) |
| Serum creatinine | |||
| Grade I–II | 0 (0) | 1 (5.3) | 0 (0) |
| Grade III–IV | 0 (0) | 0 (0) | 0 (0) |
| Chest pain | |||
| Grade I–II | 3 (12.5) | 2 (10.5) | 0 (0) |
| Grade III–IV | 0 (0) | 0 (0) | 0 (0) |
| Fever | |||
| Grade I–II | 3 (12.5) | 1 (5.3) | 0 (0) |
| Grade III–IV | 0 (0) | 0 (0) | 0 (0) |
| Nausea/vomiting | |||
| Grade I–II | 2 (8.3) | 3 (15.8) | 3 (5.2) |
| Grade III–IV | 0 (0) | 0 (0) | 0 (0) |
BLM, bleomycin; TKI, tyrosine kinase inhibitor.